Amphastar Pharmaceuticals Stockholders Approve Key Amendments

An announcement from Amphastar Pharmaceuticals ( (AMPH) ) is now available.

At the 2025 Annual Meeting of Stockholders held on June 2, 2025, Amphastar Pharmaceuticals‘ stockholders approved several key amendments to the company’s Charter and Bylaws. These included changes to reflect Delaware law provisions regarding officer exculpation and the removal of the forum selection provision. Additionally, the election of three Class III directors, the ratification of Ernst & Young LLP as the independent accounting firm, and the approval of executive compensation were confirmed. These decisions are expected to impact the company’s governance structure and operational flexibility, potentially influencing its strategic direction and stakeholder relations.

The most recent analyst rating on (AMPH) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Amphastar Pharmaceuticals stock, see the AMPH Stock Forecast page.

Spark’s Take on AMPH Stock

According to Spark, TipRanks’ AI Analyst, AMPH is a Outperform.

Amphastar Pharmaceuticals scores a 70, reflecting strong financial performance and potential value at its current valuation. However, recent earnings call insights highlight challenges from increased competition and financial pressures. Technical analysis indicates bearish momentum, suggesting cautious optimism for future performance.

To see Spark’s full report on AMPH stock, click here.

More about Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development, manufacture, and marketing of generic and proprietary injectable, inhalation, and intranasal products. The company is known for its emphasis on delivering cost-effective solutions in the healthcare market.

Average Trading Volume: 599,804

Technical Sentiment Signal: Sell

Current Market Cap: $1.2B

For an in-depth examination of AMPH stock, go to TipRanks’ Stock Analysis page.